Key Takeaways:

  • The FDA sent warning letters to 30 telehealth companies on March 3, 2026, for illegal marketing of compounded GLP-1 medications
  • This represents the largest enforcement action in GLP-1 compounding history, surpassing all letters sent in the previous decade
  • Companies were cited for claiming compounded drugs were equivalent to FDA-approved medications and obscuring their actual sources
  • Three people required emergency room visits after taking products from one cited company

The Food and Drug Administration has launched its most aggressive crackdown yet on compounded GLP-1 medications, sending warning letters to 30 telehealth companies on March 3, 2026, for making false or misleading claims about compounded versions of popular weight loss drugs like semaglutide and tirzepatide.

"It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action," said FDA Commissioner Marty Makary. This enforcement wave represents a dramatic shift from the agency's previous approach to regulating the booming compounded GLP-1 market.

Record-Breaking Enforcement Action

Over the past six months, the FDA has sent thousands of letters warning pharmaceutical and telehealth firms to remove misleading ads, more than had been sent over the entire preceding decade. The March 3 action specifically targeted companies that were making claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification.

The warning letters represent the second group sent to telehealth firms since the agency launched in September a crackdown on misleading direct-to-consumer pharmaceutical advertisements. Unlike previous enforcement efforts that many in the industry viewed as "compliance theater," these actions have real teeth and immediate consequences for companies that don't comply.

FDA officials accused the companies of making false or misleading claims about compounded GLP-1 products, with violations including suggesting that compounded medications were FDA-approved when they're not, and implying that compounded versions were identical to brand-name drugs like Wegovy and Zepbound.

Growing Safety Concerns Drive Crackdown

The crackdown comes as Novo estimated 1 million people were taking a compounded GLP-1 medicine last year, despite drug shortages officially ending. About 80% of compound semaglutide and tirzepatide prescriptions now have supplemental ingredients like B vitamins, which manufacturers are adding to justify continued compounding even though shortages have resolved.

The safety concerns are real and mounting. Three people were directed to the emergency room after taking products compounded by GenoGenix, one of the companies cited in the warning letters. The FDA found that GenoGenix was repackaging semaglutide, tirzepatide and even retatrutide (Eli Lilly's experimental drug) while also compounding medicines including 5-amino-1-methylquinolinium iodide and nicotinamide adenine dinucleotide.

The FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels do not exist. In other cases, the labels contain the name of a licensed pharmacy that did not compound these products.

Quality Control Problems Revealed

Some companies are selling "compound" drugs with imported active pharmaceutical ingredients from plants that aren't inspected by the FDA, and some illegitimate GLP-1 copycats may contain salt forms of semaglutide with active ingredients that are different from those approved for compounding.

Injectable GLP-1 receptor agonists require refrigeration, but the FDA has received complaints that some compounded versions arrived warm or improperly cooled. The agency has also identified fraudulent compounded semaglutide and tirzepatide products with false or misleading labels.

The FDA has received reports of adverse events requiring hospitalization linked to dosing errors and the use of compounded products at doses exceeding FDA-approved labeling. Reported symptoms include nausea, vomiting, diarrhea, abdominal pain, and constipation.

Industry Partnerships Signal New Direction

The enforcement action came days before a major industry development that signals how companies are responding to regulatory pressure. Novo Nordisk and Hims & Hers announced on March 9, 2026, that they had resolved their dispute and entered into a new partnership. Under the agreement, Hims & Hers will offer Novo Nordisk's branded semaglutide products on its telehealth platform, while ceasing its advertising and marketing of compounded GLP-1 drugs except where medically necessary.

FDA Commissioner Makary publicly endorsed the deal, and the resolution may serve as a template for how other telehealth companies navigate the evolving regulatory landscape. This partnership model could become the new standard as the FDA continues its enforcement push.

What This Means for You

If you're currently using or considering compounded GLP-1 medications, this enforcement action signals that the regulatory landscape is changing rapidly. The days of easily accessing low-cost compounded versions with questionable quality controls are ending.

Your best option is to work with licensed healthcare providers who can help you access FDA-approved medications through legitimate channels. Many telehealth providers are now partnering directly with manufacturers to offer brand-name drugs at competitive prices, which may be safer and more reliable than compounded alternatives.

If cost is your primary concern, explore the pricing options available for FDA-approved medications, including patient assistance programs and new lower-cost options. You can also research FDA-approved semaglutide and tirzepatide options that may fit your budget better than risky compounded versions.

Don't let this enforcement action discourage you from exploring legitimate GLP-1 options. The crackdown actually helps ensure that the medications available to you meet proper safety and quality standards.